Abstract:Objectives: Identifying high-grade serous ovarian cancer (HGSOC) at its early or preinvasive stage is paramount in improving ovarian cancer (OC) mortality. In contrast to the conventional approaches relying on assessing tumor-released proteins, or imaging assessment, we hypothesized that it is feasible to identify cancer signals from the adaptive immune system. It has been reported that shared sequence similarity in the hypervariable CDR3 region of the T cell receptors (TCR) can be used as a surrogate for shared antigen-specificity. Under this observation, clustering similar TCRs has proven powerful in identifying antigen-specific T cell groups. Our objective was to demonstrate a distinct T cell immune repertoire signature for HGSOCs. Methods: Targeted TCR repertoire sequencing using the immunoSEQ platform was performed on blood samples from cancer patients and healthy controls in the public domain. The CDR3 regions from these patients were used as training data to develop a computational framework to systematically investigate TCR repertoires in cancer patients. ImmunoSEQ platform was performed on blood samples from 45 non-treated HGSOCs, ten non-HGSOCs, 31 benign cysts, and 34 healthy controls collected under an IRB-approved protocol. This data was used as a proof-of-principle analysis of our computational framework to differentiate ovarian cancers from benign cysts and healthy controls. Results: Our training data consisted of 20 million cancer-associated TCR sequences and 500,000 non-cancer TCR extracted from 50 healthy donors. Pooled TCRs from the above samples were partitioned into 5,000 clusters. The centroid of each cluster represents an antigen-specific TCR signature, referred to as ‘repertoire functional unit’ (RFU). Each RFU can be perceived as a ‘gene’ of the TCR repertoire, which is responsible for recognizing a class of unknown antigens. Although their antigen-specificities remain uncharacterized, the relative abundance of RFUs in each repertoire can reveal important information of the disease signatures, including ovarian cancer. With this transformation, each repertoire sample was converted into a 5,000 vector of the frequency of the same RFUs, disregarding the large diversity of the original CDR3 sequences. An unsupervised principal component analysis (PCA) of the sample-by-RFU matrix was able to differentiate HGSOCs from benign and normal controls (p=2.5, 10-6, one-way ANOVA). We next performed a proof-of-principal analysis by using the RFUs as predictors for a cohort of 120 HGSOC and control patients collected from our biore-pository. We showed that a simple machine learning model using different numbers of selected RFUs achieved high prediction accuracies ranging from 97.3% to 100%. Conclusions: This result suggested that the HGSOC tumor significantly altered the blood TCR repertoire composition, causing a sufficient shift in the RFU composition that dominated the variation between cancer and non-cancer samples. Proof-of principle analysis demonstrates a strong and distinctive immune repertoire signature of HGSOCs with high prediction accuracy.

Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens

Harnessing Tumor Immunogenomics: Tumor Neoantigens in Ovarian Cancer and Beyond

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancer

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.

Antigen-specific immunotherapy of cervical and ovarian cancer

In silico Identification of MHC Displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells

MtHsp70-CLIC1-pulsed Dendritic Cells Enhance the Immune Response Against Ovarian Cancer.

Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value As a Biomarker

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer

Eliciting Effective Tumor Immunity Against Ovarian Cancer by Cancer Stem Cell Vaccination

Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens

A TEMPORAL MODEL OF TUMOR-IMMUNE DYNAMICS IN HIGH GRADE SEROUS OVARIAN CANCER

Ubiquitin-related gene markers predict immunotherapy response and prognosis in patients with epithelial ovarian carcinoma

The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy

Genome-Scale Search of Tumor-Specific Antigens by Collective Analysis of Mutations, Expressions and T-Cell Recognition

Detection of high-grade serous ovarian carcinoma using adaptive immune response and T cell repertoire (201)

Overexpression Of Trophoblast Cell Surface Antigen 2 As An Independent Marker For A Poor Prognosis And As A Potential Therapeutic Target In Epithelial Ovarian Carcinoma